Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study ID
NCT05950139
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • ALK Fusion Protein Expression
  • NSCLC Stage IV

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Peptide vaccine — BIOLOGICAL
    Peptide vaccine

Study Details

The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.

Key Dates

Start date
May 13, 2024
Status verified
Sep 2025
Primary completion
Jul 31, 2026
Completion
Jul 31, 2029

Study Design

Enrollment
12 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Advanced ALK+ NSCLC
    All patients will receive the intervention

Primary Outcome Measure

Incidence of treatment-related adverse events [ Time Frame: Up to 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Johns Hopkins UniversityBaltimoreMaryland21287
Vincent Lam, MD
[email protected]
410-955-8964
Vincent Lam, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Baltimore, MD

By research site
Johns Hopkins University· Baltimore, MD

Related Studies